Zobrazeno 1 - 10
of 156
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Eric Lawitz, Manuel Romero-Gómez, Quentin M. Anstee, Stephen A. Harrison, Catherine Jia, Zobair M. Younossi, Chuhan Chung, Zachary Goodman, Robert P. Myers, Ryan S Huss, Michael Trauner, Vincent Wai-Sun Wong, Andrew J. Muir, Takeshi Okanoue, Jaime Bosch, D. Ding, Nezam H. Afdhal, Manal F. Abdelmalek, Ling Han, Arun J. Sanyal
Publikováno v:
Sanyal, Arun J; Anstee, Quentin M; Trauner, Michael; Lawitz, Eric J; Abdelmalek, Manal F; Ding, Dora; Han, Ling; Jia, Catherine; Huss, Ryan S; Chung, Chuhan; Wong, Vincent Wai-Sun; Okanoue, Takeshi; Romero-Gomez, Manuel; Muir, Andrew J; Afdhal, Nezam H; Bosch, Jaime; Goodman, Zachary; Harrison, Stephen A; Younossi, Zobair M and Myers, Robert P (2022). Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. Hepatology, 75(5), pp. 1235-1246. Wiley 10.1002/hep.32204
[Background and Aims] Surrogate endpoints that predict complications are necessary for assessment and approval of NASH therapies. We assessed associations between histologic and noninvasive tests (NITs) of fibrosis with liver‐related complications
Autor:
Colby Ayers, Kara Wegermann, Vanessa Blumer, Robert W. McGarrah, Ambarish Pandey, Cynthia A. Moylan, Anna Mae Diehl, Tarek Bekfani, Anthony E. Peters, Manal F. Abdelmalek, Marat Fudim, Justin L. Grodin
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 842-848 (2021)
ESC Heart Failure
ESC Heart Failure
Aims Non‐alcoholic fatty liver disease leads to progressive liver fibrosis and appears to be a frequent co‐morbid disease in heart failure with preserved ejection fraction (HFpEF). It is well known that liver fibrosis severity predicts future liv
Autor:
Sven Francque, Manal F. Abdelmalek, Veronica Miller, Claudia Filozof, Elmer Schabel, Katherine Barradas, Mazen Noureddin, Mark Berner-Hansen, Jörn M. Schattenberg, Stephanie O Omokaro, Oliver Glass
Publikováno v:
Journal of hepatology
Lifestyle modification is the foundation of treatment recommendations for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The design of clinical trials in NASH may be impeded by the lack of a systematic approach to
Autor:
Rohan Khera, Kara Wegermann, Manal F. Abdelmalek, Kershaw V. Patel, Lin Zhong, Cynthia A. Moylan, Anna Mae Diehl, Robert W. McGarrah, Vishal N. Rao, Ethan A. Halm, Ian J. Neeland, Marat Fudim, Ambarish Pandey, Sandeep R Das, Jeroen Molinger
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 22 (2021)
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Nonalcoholic fatty liver disease (NAFLD) and heart failure (HF) are increasing in prevalence. The independent association between NAFLD and downstream risk of HF and HF subtypes (HF with preserved ejection fraction and HF with reduced ejec
Autor:
Guadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, Stephen A. Harrison, Manal F. Abdelmalek, Eric Lawitz, Sanjaya K. Satapathy, Marwan Ghabril, Mitchell L. Shiffman, Ziad H. Younes, Paul J. Thuluvath, Annalisa Berzigotti, Agustin Albillos, James M. Robinson, David T. Hagerty, Jean L. Chan, Arun J. Sanyal, M. Abdelmalek, K. Bhamidimarri, B. Borg, S. Caldwell, J. Fenkel, B. Freilich, M. Fuchs, M. Ghabril, R. Ghalib, S. Gonzalez, S. Gordon, B. Hameed, S. Harrison, Z. Kayali, N. Kemmer, K. Korenblat, M. Lai, C. Landis, E. Lawitz, W. Lee, S. Lidofsky, E. Mena, M. Noureddin, A. Paredes, N. Pyrsopoulos, R. Reddy, M. Rinella, D. Rockey, M. Rodriguez, M. Ryan, S. Sarkar, S. Satapathy, A. Scanga, M. Shiffman, M. Siddiqui, D. Simonetto, W. Syn, P. Thuluvath, R. Vemulapalli, J. Vierling, Z. Younes, A. Albillos, J. Arenas Ruiz-Tapiador, S. Augustin, J. Calleja, J. Crespo Garcia, L. Garcia Buey, J.C. Garcia-Pagan, C. Villanueva, C. Bureau, N. Carbonell, V. Leroy, P.-E. Rautou, H. Heinzow, I. Schiefke, A. Zipprich, A. Berzigotti, B. Muellhaupt
Publikováno v:
Garcia-Tsao, Guadalupe; Bosch, Jaime; Kayali, Zeid; Harrison, Stephen A; Abdelmalek, Manal F; Lawitz, Eric; Satapathy, Sanjaya K; Ghabril, Marwan; Shiffman, Mitchell L; Younes, Ziad H; Thuluvath, Paul J; Berzigotti, Annalisa; Albillos, Agustin; Robinson, James M; Hagerty, David T; Chan, Jean L; Sanyal, Arun J (2020). Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension. Journal of hepatology, 72(5), pp. 885-895. Elsevier 10.1016/j.jhep.2019.12.010
Background & Aims Emricasan, an oral pan-caspase inhibitor, decreased portal pressure in experimental cirrhosis and in an open-label study in patients with cirrhosis and severe portal hypertension, defined as a hepatic venous pressure gradient (HVPG)
Autor:
Anna Mae Diehl, Ning-Ping Zhang, Ying Wang, Chen Yang, Xiuping Liu, Xue-Jing Liu, Wen‐Yue Dong, Chang Liu, Li Xie, Manal F. Abdelmalek, Jian Wu, Chenjian Gu, Kuo Du, Chen Niu
Publikováno v:
Liver Int
Background and aims Treatment of non-alcoholic steatohepatitis (NASH) is challenging, because suppressing fibrotic progression has not been achieved consistently by drug candidates currently in clinical trials. The aim of this study was to investigat
Autor:
Elizabeth K. Fletcher, Athan Kuliopulos, Nga Nguyen, Srijoy Guha, Andrew Shearer, Daniel H. Cox, James D. Baleja, Ying Wang, Manal F. Abdelmalek, Lidija Covic, Rajashree Rana
Publikováno v:
Molecular Metabolism, Vol 29, Iss, Pp 99-113 (2019)
Molecular Metabolism
Molecular Metabolism
Objective Increases in hepatic and plasma cholesterol occur in patients with nonalcoholic fatty liver disease (NAFLD), although the reason for this is not well understood. We investigated whether Protease-Activated Receptor 2 (PAR2) plays a role in c
Autor:
Jun Zhang, Roger J. Davis, Meng Li, Christopher Q. Chen, Anna Mae Diehl, Mariam Aghajan, Ying Wang, Robert Win Maw Min, Tin Aung Than, Sanda Win, Neil Kaplowitz, Yibu Chen, Manal F. Abdelmalek, Filbert W.M. Aung, Ayako Suzuki
Publikováno v:
Journal of Clinical Investigation. 129:5278-5293
SH3 domain–binding protein that preferentially associates with Btk (SAB) is an outer-membrane docking protein for JNK-mediated impairment of mitochondrial function. Deletion of Sab in hepatocytes inhibits sustained JNK activation and cell death. Th
Autor:
De Lisa Fairweather, Sanda Win, Stefano Ballestri, Tin Aung Than, Amedeo Lonardo, Fabio Nascimbeni, Ayako Suzuki, Manal F. Abdelmalek
Publikováno v:
Hepatology
Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex differences in NAFLD remains insufficient. This review summarizes the current knowledge on sex differences in NAFLD, identifies gaps, and d
Autor:
Anna Mae Diehl, Oliver Glass, Elizabeth Bechard, Jane F. Pendergast, Cynthia D. Guy, Daniel Liu, Manal F. Abdelmalek
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 6, Iss 2, Pp 334-344 (2022)
Hepatology Communications, Vol 6, Iss 2, Pp 334-344 (2022)
Exercise is a foundational treatment for nonalcoholic fatty liver disease (NAFLD); however, the majority of patients are unable to initiate and maintain effective exercise habits and remain at increased risk for progressive liver disease. Barriers an